Skip to content
Markets News
Stocks1 min read

OSE Reports Higher One-Year Survival With Tedopi Combinations

Makkler Newsroom
October 19, 2026 · Based on reporting by GlobeNewswire

OSE Immunotherapeutics said both Tedopi combinations met the primary endpoint in a Phase 2 lung cancer trial, with results due at ESMO.

Key takeaways

  • One-year survival was 47% with Tedopi plus docetaxel and 46% with Tedopi plus nivolumab.
  • Treatment-related adverse events occurred in 89% and 82% of patients in the combination groups.

OSE Immunotherapeutics said Tedopi combinations met the primary endpoint in a Phase 2 trial of second-line treatment for metastatic non-small cell lung cancer. One-year overall survival was 47% with Tedopi plus docetaxel and 46% with Tedopi plus nivolumab.

The company said both rates were statistically significant, while the docetaxel-only group had a one-year survival rate of 29%, which was not statistically significant. Bayesian analyses indicated a greater than 90% probability that each combination improved one-year survival versus docetaxel alone.

Treatment-related adverse events occurred in 89% of patients receiving Tedopi plus docetaxel, 82% with Tedopi plus nivolumab and 79% with docetaxel alone. OSE reported no unexpected safety signals.

Lead investigator Federico Cappuzzo is due to present the final results on October 25 at the ESMO annual meeting in Madrid. OSE said its Phase 3 ARTEMIA study of Tedopi alone is recruiting patients, with results expected in early 2028.

Topics
OSETedopi
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.